The therapeutic effect of ccRCC has been significantly improved in recent decades, and immunotherapies such as PD1, PDL1, and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors have been approved for clinical treatment.9, 30, 31. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.